- MicroPort Scientific swung to net profit of US$38.4 million in 2025 as revenue rose 6% to US$1.1 billion.
- Non-GAAP operating profit turned positive at US$0.3 million, while net cash from operating activities improved to US$69.1 million.
- Management said revenue tied to its GloMatrix commercialization platform climbed 78.8% to US$163.9 million, reaching breakeven for the year.
- Strategic integration of structural heart disease and cardiac rhythm management businesses was completed, with the group pushing into heart failure treatment across monitoring, diagnosis, treatment, and management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12085583), on March 31, 2026, and is solely responsible for the information contained therein.
Comments